ZIANA (clindamycin phosphate and tretinoin) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2006.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
ZIANA is a fixed-dose topical gel combining clindamycin phosphate (antibiotic) and tretinoin (retinoid) approved for acne vulgaris. Clindamycin inhibits bacterial protein synthesis against Propionibacterium acnes, while tretinoin decreases follicular epithelial cohesiveness and stimulates cell turnover to extrude comedones. The combination addresses both bacterial infection and structural acne pathology in a single formulation.
ZIANA faces LOE pressure with minimal Part D spending ($10K in 2023, only 15 claims), indicating a niche or declining market position requiring transition planning.
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ZIANA careers are contracting as LOE approaches with minimal Part D uptake; roles focus on defensive brand management, channel optimization, and transition support. Working on ZIANA offers experience in mature dermatology markets and generic defense strategy, but limited growth trajectory or career acceleration.
Worked on ZIANA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo